Jon Posey, MD
Urology · Tupelo, MSNPI 1013917103
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,842 of the $12,774 with a category attached, or 69.2%. 32 manufacturers reported payments, led by Procept Biorobotics Corporation at 25.9% of the total. Reporting peaked in 2019 at $5,389 and has fallen 77.1% since, to $1,232 in 2025. Among urology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $39.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- Neotract Inc.$1K
- Medtronic$1K
- Teleflex LLC$1K
- Axonics, Inc.$987
- Boston Scientific$828
- plus $4K from 26 others
What the payments were for
- Travel & lodging$3,81130%
- Food & beverage$8,84269%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 16 | $3,303 |
| Neotract Inc. | 21 | $1,386 |
| Medtronic(2 entities) | 50 | $1,372 |
| Teleflex LLC | 19 | $1,034 |
| Axonics, Inc. | 42 | $987 |
| Boston Scientific | 12 | $828 |
| Astellas Pharma US Inc | 53 | $791 |
| Dendreon Pharmaceuticals LLC | 9 | $460 |
| Myriad Genetic Laboratories, Inc. | 8 | $373 |
| Sumitomo Pharma America, Inc. | 18 | $357 |
| Dornier Medtech America, Inc | 1 | $272 |
| Bayer | 14 | $259 |
| Laborie Medical Technologies Corp. | 2 | $169 |
| Cook Medical LLC | 2 | $163 |
| Urogen Pharma, Inc. | 9 | $142 |
| AbbVie(2 entities) | 7 | $117 |
| Olympus Corporation Of The Americas | 1 | $111 |
| Merck | 5 | $100 |
| Pfizer | 5 | $83 |
| Johnson & Johnson | 5 | $78 |
| 180 Medical, Inc. | 3 | $65 |
| Olympus America Inc. | 3 | $54 |
| Blue Earth Diagnostics | 2 | $50 |
| Amgen | 3 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $32 |
| Cumberland Pharmaceuticals, Inc. | 2 | $31 |
| AstraZeneca | 2 | $28 |
| Immunitybio, Inc. | 1 | $24 |
| Innovation Technologies Inc | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Coloplast | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$2,964
- UroLift$986
- INTERSTIM$619
- GENERAL BPH$441
- Dornier MedTech$272
- PROVENGE$265
- UroLift System$249
- Prolaris$249
- Axonics$237
- Barrigel$180
- Cook$143
- Bulkamid$117
- iTIND System$111
How this compares
$12,774 in reported general payments places this provider in the 95th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 157 | $395,029 |
| GemtesaVibegron | 84 | $47,674 |
| MyrbetriqMirabegron | 24 | $15,076 |
| Methenamine Hippurate | 159 | $9,034 |
| Estradiol | 63 | $4,244 |
| Tamsulosin Hcl | 315 | $2,286 |
| Tolterodine Tartrate ErTolterodine Tartrate | 56 | $2,171 |
| Silodosin | 15 | $1,792 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 227 | $545 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 65 | $444 |
| Finasteride | 28 | $427 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $422 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 30 | $338 |
| Trospium Chloride | 12 | $311 |
| Cephalexin | 36 | $281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $357 | $442,703241 claims |
| Astellas Pharma US IncMyrbetriq | $791 | $15,07624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 urology providers in Mississippi.
Other urology in Tupelo
- Kristopher WhiteheadTupelo$17K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Jeremy ArcherTupelo$6K
- Jonathan KalishTupelo$4K
- William MilamTupelo$2K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Harold BlalockJackson$15K
- Patrick DailyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.